> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Relmada Expects Its $202.1 Million Cash Base To Fund Trials And Operations Through 2029
- URL: https://www.bullished.co/relmada-expects-its-202-1-million-cash-base-to-fund-trials-and-operations-through-2029-b79682bd/
- Published: 2026-11-12T21:25:54.000Z
- Updated: 2026-11-12T21:25:54.000Z
- Description: Early bladder-cancer follow-up showed lasting responses, but two patients progressed to muscle-invasive disease.
- Author: Matteo Parrino
- Tags: SEC Filings, RLMD, Industry: Healthcare

Relmada Therapeutics, which is testing bladder-cancer treatment NDV-01, expects approximately [$202.1 million](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-1.htm?ref=bullished.co) in cash and short-term investments to cover operations through 2029, including both pivotal bladder-cancer study groups. The company released the preliminary, unaudited third-quarter results Thursday alongside an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea0312057-8k%5Frelmada.htm?ref=bullished.co).

## Longer Responses, With Progression In Two Patients

The initial, preliminary extension results showed that [12 of 14](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-1.htm?ref=bullished.co) evaluable patients who had no detectable cancer at 12 months still had complete responses at 18 months—86%. Of 23 patients entering extended follow-up, 14 had reached the 18-month assessment.

Among patients whose disease had not responded to BCG, a bladder-cancer treatment, seven of eight evaluable patients retained complete responses at 18 months, or 88%. Eleven patients in that subgroup entered the extension.

Two patients who had not previously received BCG developed muscle-invasive cancer at the 15-month assessment. Through 12 months, no patients had progressed or undergone bladder removal; the company's updated presentation showed [no bladder removals](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-2.htm?ref=bullished.co) through 18 months.

The updated core study included 51 evaluable patients. Complete responses occurred at some point in 48 patients, or 94%; at 12 months, 24 of 31 evaluable patients had complete responses, or 77%. The BCG-unresponsive subgroup's corresponding rates were 96% and 73%.

No severe treatment-related adverse events, treatment-related serious events or treatment-related discontinuations were reported. Treatment-related side effects nevertheless occurred in 35 of 51 patients, or 69%, including uncomfortable urination, blood in urine and urinary urgency or frequency.

## Cash Backing For SPECTRUM

Relmada has no approved products and has not generated revenue. NDV-01 combines gemcitabine and docetaxel in a controlled-release treatment delivered into the bladder for cancer that has not invaded the bladder muscle.

The company targets year-end 2026 applications seeking FDA permission to begin trials of NDV-01 and sepranolone. It expects the late-stage SPECTRUM bladder-cancer program and a mid-stage sepranolone study in Prader-Willi syndrome to start after clearance. Sepranolone's pre-filled syringe is undergoing final stability testing.

SPECTRUM, renamed from RESCUE, retains its two independent paths toward potential approval. One studies high-risk patients whose disease failed prior treatments; the other compares NDV-01 with observation after tumor removal in intermediate-risk patients. A [separate exploratory group](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-2.htm?ref=bullished.co) is not intended to support approval. Trial sites are preparing for enrollment.

Relmada Chief Executive Officer Sergio Traversa said the company has a manufacturing plan to provide "[uninterrupted clinical supply](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-1.htm?ref=bullished.co) through the completion of the Phase 3 SPECTRUM program."

## Research Spending Rises, Administration Falls

First-quarter stock issuance brought in $150.4 million in net proceeds. Cash and short-term investments stood at approximately $93.0 million at year-end 2025.

Third-quarter research spending rose by $5.2 million to $9.2 million from $4.0 million a year earlier. Relmada attributed the increase mainly to study preparation, manufacturing, storage and employee pay, partly offset by lower stock-based compensation.

Administrative spending fell by approximately $2.4 million to $3.9 million from $6.3 million. The company attributed the decline chiefly to lower stock-based compensation and stock appreciation rights expense, partly offset by higher employee pay and consulting costs.

Quarterly operating cash use rose to $12.6 million from $6.7 million. Net loss widened to $13.9 million from $10.1 million, while loss per share narrowed to $0.12 from $0.30.

For the first nine months, research spending reached $25.7 million versus $18.8 million, and administrative spending totaled $21.9 million versus $20.0 million. Operating cash use was $37.3 million versus $31.2 million; net loss was $45.8 million, or $0.44 per share, versus $37.5 million, or $1.16 per share.

Relmada's funding forecast includes completion of both pivotal SPECTRUM groups; their launch remains dependent on FDA clearance of the planned trial application.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — RELMADA THERAPEUTICS, INC. (RLMD)](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea0312057-8k%5Frelmada.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea031205701ex99-1.htm — RELMADA THERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea031205701ex99-2.htm — RELMADA THERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001553643/000121390026118933/ea031205701ex99-2.htm?ref=bullished.co) — SEC EDGAR